



Docket No.: 275596US96X PCT

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/517,600

Applicants: Haruo SUGIYAMA, et al.

Filing Date: December 13, 2004

For: HLA-A24-RESTRICTED CANCER ANTIGEN
PEPTIDES

Group Art Unit:

Examiner:

SIR:

Attached hereto for filing are the following papers:

Notification of Defective Response - Attorney/Applicant Copy

Preliminary Amendment and Statement - 3 pp.

Substitute Sequence Listing (paper, 20 pp.)

Computer-Readable Sequence Listing (Diskette)

Our check in the amount of **\$0.00** is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R. 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.


Charles J. Andres Jr., Ph.D.
Registration No. 57,537

Customer Number

22850

(703) 413-3000 (phone)
(703) 413-2220 (fax)



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/517,600	Haruo Sugiyama	0020-5329PUS1
		INTERNATIONAL APPLICATION NO.
		PCT/JP03/07463
22850 C. IRVIN MCCLELLAND OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET ALEXANDRIA, VA 22314		I.A. FILING DATE PRIORITY DATE
		06/12/2003 06/12/2002

CONFIRMATION NO. 4687
 371 FORMALITIES LETTER



OC000000020469504

Date Mailed: 09/18/2006

2755964596KPC

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495)

- Priority Document
- Copy of the International Application filed on 12/13/2004
- English Translation of the IA filed on 12/13/2004
- Copy of the International Search Report filed on 12/13/2004
- Copy of IPE Report filed on 12/13/2004
- Preliminary Amendments filed on 12/13/2004
- Information Disclosure Statements filed on 12/13/2004
- Biochemical Sequence Diskette filed on 06/24/2005
- Oath or Declaration filed on 12/13/2004
- Biochemical Sequence Listing filed on 10/06/2005
- Request for Immediate Examination filed on 12/13/2004
- U.S. Basic National Fees filed on 12/13/2004
- Priority Documents filed on 12/13/2004
- Power of Attorney filed on 10/06/2005
- Specification filed on 12/13/2004
- Claims filed on 12/13/2004
- Abstracts filed on 12/13/2004
- Drawings filed on 12/13/2004

RECEIVED: 9/2006
 OBLON, SPIVAK, MCCLELLAND
 MAIER & NEUSTADT, P.C.
 DOCKETING DEPT.
 Initials/Date Docketed: W09 2006
 Type of Response: Receipt w/n-resp.
 Due Date(s): 10/18/06 (AO 7-60)

Applicant's response filed 10/06/2005 is hereby acknowledged. The following requirements set forth in the NOTIFICATION of MISSING REQUIREMENTS mailed 06/03/2005 have not been completed.

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

KAREN M WILLIAMS

Telephone: (703) 308-9140 EXT 213

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/517,600	PCT/JP03/07463	0020-5329PUS1

FORM PCT/DO/EO/916 (371 Formalities Notice)